Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1699-1706

  Li, Tao ^a   Yin, Jikai ^a   Yuan, Lijuan ^a   Wang, Shouli ^a   Yang, Lin ^a   Du, Xilin ^a   Lu, Jianguo ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Hepatocellular carcinoma; MicroRNA; MicroRNA 139; Survival analysis

Indexed keywords

ALPHA FETOPROTEIN; MICRORNA; MICRORNA 139; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER TISSUE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SHORT TERM SURVIVAL; SURVIVAL RATE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84908126667     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3032     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Srivatanakul P, Sriplung H and Deerasamee S: Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 5: 118-125, 2004.
3. Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339-346, 2002.
4. Marrero JA and Lok AS: Newer markers for hepatocellular carcinoma. Gastroenterology 127 (Suppl 1): S113-S119, 2004.
5. Jannot G and Simard MJ: Tumour-related microRNAs functions in Caenorhabditis elegans. Oncogene 25: 6197-6201, 2006.
6. Lujambio A and Lowe SW: The microcosmos of cancer. Nature 482: 347-355, 2012.
7. Meng F, Henson R, Lang M, et al: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130: 2113-2129, 2006.
8. Xia L, Zhang D, Du R, et al: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 123: 372-379, 2008.
9. Budhu A, Jia HL, Forgues M, et al: Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47: 897-907, 2008.
10. Calin GA, Ferracin M, Cimmino A, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353: 1793-1801, 2005.
11. Luo X, Burwinkel B, Tao S and Brenner H: MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol Biomarkers Prev 20: 1272-1286, 2011.
12. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3: 1101-1108, 2008.
13. Marrero JA, Feng Z, Wang Y, et al: α-fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137: 110-118, 2009.
14. Shih WL, Chang HC, Liaw YF, et al: Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer 131: 2612-2621, 2012.
15. Edmondson HA and Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7: 462-503, 1954.
16. Child CG and Turcotte JG: Surgery and portal hypertension. Major Probl Clin Surg 1: 1-85, 1964.
17. No authors listed: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28: 751-755, 1998.
18. Sherman M: Approaches to the diagnosis of hepatocellular carcinoma. Curr Gastroenterol Rep 7: 11-18, 2005.
19. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
20. Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin 62: 394-399, 2012.
21. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
22. Lawrie CH, Gal S, Dunlop HM, et al: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675, 2008.
23. Tomimaru Y, Eguchi H, Nagano H, et al: Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 56: 167-175, 2012.
24. Bao W, Fu HJ, Xie QS, et al: HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology 141: 2076-2087, 2011.
25. Shen K, Liang Q, Xu K, et al: MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochem Pharmacol 84: 320-330, 2012.
26. Schmitz KJ, Helwig J, Bertram S, et al: Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol 64: 529-535, 2011.
27. Corbetta S, Vaira V, Guarnieri V, et al: Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer 17: 135-146, 2010.
28. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP and Wei WI: Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 14: 2588-2592, 2008.
29. Wong CC, Wong CM, Tung EK, et al: The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology 140: 322-331, 2011.
30. Au SL, Wong CC, Lee JM, et al: Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 56: 622-631, 2012.
31. Ker CG, Chen HY, Chen KS, et al: Clinical significance of cell differentiation in hepatocellular carcinoma. Hepatogastroenterology 50: 475-479, 2003.